CAMBRIDGE, Mass., June 12 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, today announced that it’s co-founder, president and CEO, Dr. Keith O. Elliston, will be actively sharing his expertise in translational medicine this week at the Second Annual Disease Models Conference, which is part of Cambridge Healthtech Institute’s Sixth Annual World Pharmaceutical Congress being held in Philadelphia June 12 and 13, 2007.
Dr. Elliston has been invited to make a presentation, chair a session and participate in two panel discussions at this conference focusing on translational models for diseases. His presentation on Tuesday, June 12, will be on “Cross Species Comparative Models”, where he will discuss how systems biology analyzes biological processes as an integrated, interactive network of genes, proteins and metabolites and uses this knowledge to define mechanistic biomarkers. Dr. Elliston will also be chairing a session on “Comparing and Sharing” Tuesday morning at 10:20. At 2:35 Tuesday afternoon, he will be participating in a panel discussion on “The Power of Interspecies Differences & Predictive Value - Translation to Human” and at 11:10 a.m. on Wednesday, Dr. Elliston will be on a panel focused on “Computational Biology & Analysis - Effectively Translating Data.”
“This conference recognizes Genstruct’s increasing role in translational medicine,” explained Keith O. Elliston, Ph.D., president and CEO of Genstruct. “As a firm that specializes in using sophisticated computer modeling to translate the complexity of human biology into the actionable insights that drive the successful development of human therapeutics, we look to not only share our expertise in this area, but to also learn from the other experts at the conference and continually make strides forward in the translation from experimental models to the clinic.”
Dr. Elliston is an invited speaker at many biotechnology and pharmaceutical industry events. He is an experienced entrepreneur and intrapreneur who has dedicated his career to the development of leading-edge technology for drug discovery. Dr. Elliston spent over 10 years with Merck Research Laboratories, where he served as the Director of Bioinformatics, and the scientific director of the Merck Gene Index project. He then joined Bayer Pharmaceuticals where he founded their global genomics and bioinformatics efforts, and was the section head of Genomics and the worldwide head of Bioinformatics. In 1997 Dr. Elliston joined Gene Logic as Chief Scientific Officer and pioneered the development/application of molecular profiling to drug discovery. He was responsible for the development and management of six pharmaceutical research partnerships representing over $350 million in potential revenues. In 1999, Dr. Elliston founded Viaken Systems, where he was Chairman, President and CEO. He has been an advisor to Oak Investment Partners, Atlas Ventures, and other biotechnology venture capital groups, and has participated in the early stage development of a number of successful biotech companies. Dr. Elliston received an M.S. in genetics from the University of Minnesota, and a Ph.D. in molecular genetics from Rutgers University.
About Genstruct
Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling of the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.
Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.
Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com
Genstruct Inc.
CONTACT: Karen Higgins of A & E Communications for Genstruct,+1-610-831-5723, khiggins@aandecomm.com
